ArticleCancer cell2017
Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 267 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
267citing papers in PubMed, 3 pooled it
36.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
267 citing papers in PubMed, 3 syntheses or guidelines pooled it, 470 citations in OpenAlex.
- A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation.Nature metabolism · 2023Pooled it
- Association of CCL4 rs10491121 and rs1634507 gene polymorphisms with cancer susceptibility: trial sequential analysis and meta-analysis.Frontiers in oncology · 2023Pooled it
- Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects.Frontiers in oncology · 2021Pooled it
- A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma.The oncologist · 2022Trial
- Glucosamine induces apoptosis of cholangiocarcinoma cells by suppressing high-mannose typeFuture science OA · 2026Article
- Global patterns of mutational profiles in biliary tract cancer.Journal of hepatology · 2026Article
- Noninvasive Multi-Omics Radiomic Model Integrating scRNA-seq and Bulk RNA-seq for Hepatocellular Carcinoma Prognosis.Journal of imaging informatics in medicine · 2026Article
- Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy.Cancers · 2026Review
- The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1.The Journal of clinical investigation · 2026Article
- Cuproptosis as a novel predictor of immunotherapy response and shapes the immune landscape in pan-cancer analysis.Discover oncology · 2026Article
- Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma.Biomedical reports · 2026Article
- MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth.Signal transduction and targeted therapy · 2026Article
- Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma.bioRxiv : the preprint server for biology · 2026Article
- How to efficiently establish animal models of cholangiocarcinoma: challenges and inspiration.Medical review (2021) · 2026Review
- Clinical applications of immunogenomics in hepatocellular carcinoma.Clinical and molecular hepatology · 2026Review
- Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target.Nature communications · 2026Article
- Article
- Integrated multi-omics analysis reveals comprehensive metabolism-driven tumor heterogeneity and immune microenvironment in hepatocellular carcinomas.Scientific reports · 2026Article
- Molecular characterization of the A52 murine hepatocellular carcinoma cell line.Animal models and experimental medicine · 2026Article
- Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer.Nature communications · 2026Article
207 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 14 institutions in 4 countries.
Jittiporn ChaisaingmongkolLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok 10210, Thailand; Center of Excellence on Environmental Health and Toxicology, Office of Higher Education Commission, Ministry of Education, Bangkok 10400, Thailand.
Anuradha BudhuLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Hien DangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Siritida RabibhadanaLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok 10210, Thailand.
Benjarath PupacdiLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok 10210, Thailand.
So Mee KwonLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Marshonna ForguesLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Yotsawat PomyenLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok 10210, Thailand.
Vajarabhongsa BhudhisawasdiFaculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Nirush LertprasertsukeFaculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Anon ChotirosniramitFaculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Chawalit PairojkulFaculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Chirayu U AuewarakulHRH Princess Chulabhorn College of Medical Science, Bangkok 10210, Thailand.
Thaniya SricharunratChulabhorn Hospital, Bangkok 10210, Thailand.
Kannika PhornphutkulRajavej Hospital, Chiang Mai 50000, Thailand.
Suleeporn SangrajrangNational Cancer Institute, Bangkok 10400, Thailand.
Maggie CamCenter for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Ping HeFDA, Silver Spring, MD 20993, USA.
Stephen M HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Kris YlayaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Xiaolin WuFrederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Jesper B AndersenBiotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
Snorri S ThorgeirssonLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Joshua J WaterfallGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Yuelin J ZhuGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Jennifer WallingGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Holly S StevensonGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Daniel EdelmanGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Paul S MeltzerGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Christopher A LoffredoGeorgetown University Medical Center, Washington, DC 20057, USA.
Natsuko HamaDivision of Cancer Genomics, National Cancer Center Research Institute, The University of Tokyo, Tokyo 104-0045, Japan.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, The University of Tokyo, Tokyo 104-0045, Japan; Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo 104-0045, Japan.
Robert H WiltroutCancer Inflammation Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Curtis C HarrisLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Chulabhorn MahidolLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok 10210, Thailand; HRH Princess Chulabhorn College of Medical Science, Bangkok 10210, Thailand. Electronic address: pc@cri.or.th.
Mathuros RuchirawatLaboratory of Chemical Carcinogenesis, Chulabhorn Research Institute, Bangkok 10210, Thailand; Center of Excellence on Environmental Health and Toxicology, Office of Higher Education Commission, Ministry of Education, Bangkok 10400, Thailand. Electronic address: mathuros@cri.or.th.
Xin W WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA. Electronic address: xw3u@nih.gov.
TIGER-LC Consortium
Center for Cancer Research · USNational Cancer Institute · USChulabhorn Research Institute · THChiang Mai University · THChulabhorn Hospital · THKhon Kaen University · THThe University of Tokyo · JPFrederick National Laboratory for Cancer Research · USGeorgetown University · USMaharaj Nakorn Chiang Mai Hospital · THMinistry of Education · THNational Cancer Institute of Thailand · THUnited States Food and Drug Administration · USUniversity of Copenhagen · DK
Funding
Strategies for improving early detection, diagnosis and treatment of liver cancerZIABC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$18.1MCancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9MRoles of microbiota-mediated hepatocarcinogenesisZIABC005793 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$3.3MMolecular signatures for liver cancer diagnosis and treatment stratificationZ01BC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 1999 to 2008
$1.8MMECHANISM OF VIRAL HEPATITIS-MEDIATED LIVER CARCINOGENESZ01BC005793 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 1996 to 2008
$636kIntramural NIH HHS Z01 BC005793Intramural NIH HHS Z01 BC010313
Abstract
Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We identified common molecular subtypes linked to similar prognosis among 199 Thai ICC and HCC patients through systems integration of genomics, transcriptomics, and metabolomics. While ICC and HCC share recurrently mutated genes, including TP53, ARID1A, and ARID2, mitotic checkpoint anomalies distinguish the C1 subtype with key drivers PLK1 and ECT2, whereas the C2 subtype is linked to obesity, T cell infiltration, and bile acid metabolism. These molecular subtypes are found in 582 Asian, but less so in 265 Caucasian patients. Thus, Asian ICC and HCC, while clinically treated as separate entities, share common molecular subtypes with similar actionable drivers to improve precision therapy.
Indexed as
Asian PeopleCarcinoma, HepatocellularCholangiocarcinomaCluster AnalysisHumansKaplan-Meier EstimateLiver NeoplasmsPrognosisTranscriptomecancer drivercancer genomicshepatocellular carcinomaintegrated genomicsintrahepatic cholangiocarcinomaliver cancermetabolomicsmolecular subtypesTIGER-LCtranscriptomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.